Press Releases Investors Investors Overview News & Events Overview Press Releases IR Calendar Email Alerts Company Info Overview Presentations Contacts FAQ Financial Info Overview Financial Results Income Statement Balance Sheet Cash Flow Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Board Committees Governance Documents News & Events Overview Press Releases IR Calendar Email Alerts Year All Years 2022 2021 2020 2019 2018 2017 2016 2015 2014 Jun 29, 2021 8:00am EDT H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health Sep 29, 2020 5:30pm EDT Robert Greif named Chief Executive Officer of H-CYTE Sep 03, 2020 8:30am EDT H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020 Sep 02, 2020 8:30am EDT H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020 Jan 21, 2020 8:00am EST H-CYTE Issues Letter to Shareholders Nov 18, 2019 8:00am EST H-CYTE Raises $6 Million to Accelerate FDA Approval Process of Next Generation Cellular Therapy for COPD Jul 12, 2019 8:30am EDT Medovex Corporation Announces Name Change to H-CYTE and New Ticker Symbol Jul 01, 2019 8:00am EDT Medovex Corporation Updates Name Change and Full Rebranding to H-CYTE Jun 24, 2019 8:00am EDT Medovex’s Transition to H-CYTE Underscores Biotechnology Focus Apr 29, 2019 8:00am EDT Medovex Corporation Announces Recent Management Appointments Prev 1 2 3 4 5 6 7 8 9 10 ...14 Next
Jun 29, 2021 8:00am EDT H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health
Sep 03, 2020 8:30am EDT H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020
Sep 02, 2020 8:30am EDT H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020
Nov 18, 2019 8:00am EST H-CYTE Raises $6 Million to Accelerate FDA Approval Process of Next Generation Cellular Therapy for COPD
